Why Is Breast Cancer-Focused BriaCell Therapeutics Stock Trading Over 100% On Wednesday

Core Insights - BriaCell Therapeutics' stock (BCTX) experienced a significant increase, trading at $1.94, up 213.1% with a session volume of 113.08 million compared to the average volume of 366.19 thousand [1][2] Clinical Study Results - The company announced overall survival data from its Phase 2 clinical study of Bria-IMT in combination with an immune checkpoint inhibitor for late-stage metastatic breast cancer, reporting a median overall survival of 15.6 months for recent patients treated since 2022 [1] - This median overall survival of 15.6 months shows a substantial improvement over the previously reported 13.4 months in December 2023 [1] - The patients in the study had a median of 6 prior treatments, indicating they were heavily pre-treated metastatic breast cancer patients [2] Treatment Efficacy - The Bria-IMT regimen is noted as the only investigational drug demonstrating impressive survival rates in heavily pre-treated metastatic breast cancer patients who have failed multiple prior treatments, including immune checkpoint inhibitors and antibody-drug conjugates [2]